PATH’s Center for Vaccine Innovation and Access

About CVIA

Vaccines for the world’s underserved populations

Photo: PATH/Gabe Bienczycki

Photo: PATH/Gabe Bienczycki

PATH’s Center for Vaccine Innovation and Access (CVIA) brings together expertise across every stage of vaccine research, development, and introduction to make lifesaving vaccines globally available to women, children, and communities, particularly in low resource settings. Our portfolio encompasses more than two dozen vaccine projects either in development or already in use to protect against 17 different diseases, with an emphasis on leading infectious causes of childhood deaths worldwide—pneumonia, diarrheal diseases, and malaria.

CVIA builds on PATH’s nearly 20 years of success in developing and delivering affordable vaccines to improve global health. We work along the entire vaccine development and delivery spectrum—from preclinical research, manufacturing, and formulation optimization on novel candidates through pivotal clinical evaluations and manufacturing at-scale to, ultimately, innovative approaches for new vaccine introduction and immunization system strengthening in traditionally underserved countries. We also work to strengthen the capacity of emerging-country vaccine manufacturers (including in chemistry, manufacturing, and controls), and mobilize community acceptance of and demand for immunization.

Our success in vaccine innovation depends on our deep engagement with multiple partners, including immunization program managers and ministries of health to provide crucial insights; scientists and clinical researchers to develop and evaluate novel approaches to vaccines in real-world conditions; manufacturers to accelerate development; global agencies like the World Health Organization and UNICEF; financing bodies like Gavi, the Vaccine Alliance; and governments to support immunization implementation. We work with communities to understand their needs and priorities, and commit to pricing and distribution strategies that ensure accessibility, availability, affordability, and acceptability.

CVIA projects are currently supported by grants from numerous funders, including the Bill & Melinda Gates Foundation, the US Department of Health and Human Services, and the United Kingdom’s Department for International Development. Some projects in CVIA are funded by PATH Vaccine Solutions (PVS)—an affiliate nonprofit corporation with 501(c)(3) tax-exempt status and a supporting organization of PATH. The PVS board of directors is chaired by the PATH president and CEO.

Our structure

We are structured to best apply our experience and expertise on every aspect of vaccine development and introduction across our broad portfolio.



Additional resources